Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines : Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia
© 2023 John Wiley & Sons Ltd..
Recent guidance from the World Health Organization strongly recommended hepatitis C virus (HCV) self-testing. We implemented the Vend-C pilot study to explore the effectiveness and feasibility of distributing rapid HCV antibody self-test kits to people who inject drugs via needle/syringe dispensing machines (SDMs). Over a 51-day study period between August and September 2022, we distributed HCV antibody self-test kits via two SDMs. During the study period, 63 self-test kits were dispensed, averaging 1.2 self-test kits per day. Our access methods for evaluation questionnaires failed to attract participants (n = 4). We implemented the Vend-C pilot study in direct response to recent WHO recommendations. While self-test kits were effectively distributed from the two SDMs, our evaluation methodology failed. Consequently, we cannot determine the success of linkage to care. Even so, with HCV treatment numbers dropping in Australia, innovative engagement solutions are needed, and considering the number of self-test kits provided in our pilot, the model could have an important future place in HCV elimination efforts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Journal of viral hepatitis - 31(2024), 3 vom: 01. März, Seite 151-155 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Keefe, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvh.13909 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366493892 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366493892 | ||
| 003 | DE-627 | ||
| 005 | 20240417232338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvh.13909 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM366493892 | ||
| 035 | |a (NLM)38158743 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Keefe, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines |b Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a Recent guidance from the World Health Organization strongly recommended hepatitis C virus (HCV) self-testing. We implemented the Vend-C pilot study to explore the effectiveness and feasibility of distributing rapid HCV antibody self-test kits to people who inject drugs via needle/syringe dispensing machines (SDMs). Over a 51-day study period between August and September 2022, we distributed HCV antibody self-test kits via two SDMs. During the study period, 63 self-test kits were dispensed, averaging 1.2 self-test kits per day. Our access methods for evaluation questionnaires failed to attract participants (n = 4). We implemented the Vend-C pilot study in direct response to recent WHO recommendations. While self-test kits were effectively distributed from the two SDMs, our evaluation methodology failed. Consequently, we cannot determine the success of linkage to care. Even so, with HCV treatment numbers dropping in Australia, innovative engagement solutions are needed, and considering the number of self-test kits provided in our pilot, the model could have an important future place in HCV elimination efforts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a harm reduction | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a people who inject drugs | |
| 650 | 4 | |a research methodology | |
| 650 | 4 | |a self-testing | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Jacka, David |e verfasserin |4 aut | |
| 700 | 1 | |a Douglass, Caitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Gunn, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Stoove, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Crawford, Sione |e verfasserin |4 aut | |
| 700 | 1 | |a Bryant, Mellissa |e verfasserin |4 aut | |
| 700 | 1 | |a Higgs, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Dietze, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Hellard, Margaret |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g 31(2024), 3 vom: 01. März, Seite 151-155 |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:151-155 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.13909 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 3 |b 01 |c 03 |h 151-155 | ||